Pages that link to "Q35850681"
Jump to navigation
Jump to search
The following pages link to NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells (Q35850681):
Displaying 50 items.
- The Role of HDAC6 in Cancer (Q21296746) (← links)
- PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells (Q21328686) (← links)
- PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells (Q24654958) (← links)
- Trial Watch: Proteasomal inhibitors for anticancer therapy (Q28082910) (← links)
- Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia (Q28385690) (← links)
- Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors (Q28474489) (← links)
- Discovery of novel proteasome inhibitors using a high-content cell-based screening system (Q33521189) (← links)
- Proteasome inhibitors in glioblastoma (Q33598931) (← links)
- Discovery and development of the anticancer agent salinosporamide A (NPI-0052). (Q33622960) (← links)
- Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies (Q33741142) (← links)
- Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib). (Q33742779) (← links)
- Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules (Q33775805) (← links)
- Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage (Q33798624) (← links)
- Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides (Q33836952) (← links)
- Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia (Q33889046) (← links)
- Salinosporamide Natural Products: Potent 20 S Proteasome Inhibitors as Promising Cancer Chemotherapeutics (Q34142223) (← links)
- The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors (Q34218976) (← links)
- Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity (Q34576976) (← links)
- Advances in and applications of proteasome inhibitors (Q34594744) (← links)
- Proteasome inhibitors in cancer therapy (Q34939959) (← links)
- In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells (Q35007061) (← links)
- Proteasome inhibitor patents (2010 - present). (Q35085938) (← links)
- Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. (Q35089766) (← links)
- Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation (Q35126359) (← links)
- Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors (Q35133399) (← links)
- Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma (Q35146262) (← links)
- Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs (Q35269634) (← links)
- Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models (Q35572018) (← links)
- The 26S proteasome complex: an attractive target for cancer therapy (Q35624079) (← links)
- Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein (Q35882968) (← links)
- Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim (Q35982670) (← links)
- Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside (Q35989980) (← links)
- Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products (Q36007617) (← links)
- EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism (Q36168253) (← links)
- The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. (Q36453798) (← links)
- Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo (Q36500531) (← links)
- Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia (Q36591379) (← links)
- Redox control of leukemia: from molecular mechanisms to therapeutic opportunities (Q36646486) (← links)
- From bortezomib to other inhibitors of the proteasome and beyond (Q36852277) (← links)
- Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier (Q36893244) (← links)
- Preclinical studies of novel targeted therapies (Q36998210) (← links)
- Therapeutic implications of leukemic stem cell pathways (Q37002357) (← links)
- Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials (Q37017342) (← links)
- The therapeutic potential of the proteasome in leukaemia (Q37103852) (← links)
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells (Q37176551) (← links)
- Treatment of Hodgkin lymphoma: the past, present, and future. (Q37235019) (← links)
- Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials (Q37301320) (← links)
- Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma (Q37301751) (← links)
- Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species (Q37309407) (← links)
- APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome (Q37377197) (← links)